Milestone Pharmaceuticals (MIST) Current Assets (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Current Assets came in at $192.3 million in Q1 2026, up 217.9% YoY from $60.5 million in Q1 2025, and up 71.78% on a QoQ basis from $111.9 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Current Assets (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Current Assets data on file, last reported at $192.3 million in Q1 2026.
- Quarterly Current Assets rose 217.9% year-over-year to $192.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.3 million (up 217.9% YoY) and the FY2025 annual result came in at $111.9 million, up 51.4% from the prior year.
- Current Assets grew to $192.3 million in Q1 2026, from $111.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $192.3 million in Q1 2026 to a low of $46.2 million in Q2 2025.
- A 5-year average of $90.9 million and a median of $86.7 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets sank 47.15% — and 2026, when it surged 217.9%.
- Tracing MIST's Current Assets over 5 years: stood at $71.8 million in 2022, then advanced by 1.71% to $73.0 million in 2023, then increased by 1.22% to $73.9 million in 2024, then surged by 51.4% to $111.9 million in 2025, then soared by 71.78% to $192.3 million in 2026.
- The last three Current Assets figures came in at $192.3 million (Q1 2026), $111.9 million (Q4 2025), and $86.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | 180.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 180.33 Mn |
| Mar 31, 2026 | 192.25 Mn |
| Dec 31, 2025 | 111.92 Mn |
| Sep 30, 2025 | 86.67 Mn |
| Jun 30, 2025 | 46.17 Mn |
| Mar 31, 2025 | 60.48 Mn |
| Dec 31, 2024 | 73.93 Mn |
| Sep 30, 2024 | 80.99 Mn |
| Jun 30, 2024 | 87.36 Mn |
| Mar 31, 2024 | 93.97 Mn |
| Dec 31, 2023 | 73.03 Mn |
| Sep 30, 2023 | 84.80 Mn |
| Jun 30, 2023 | 94.57 Mn |
| Mar 31, 2023 | 108.51 Mn |
| Dec 31, 2022 | 71.80 Mn |
| Sep 30, 2022 | 82.92 Mn |
| Jun 30, 2022 | 90.50 Mn |
| Mar 31, 2022 | 104.97 Mn |
| Dec 31, 2021 | 118.92 Mn |
| Sep 30, 2021 | 132.76 Mn |